key: cord-0723567-tyexaefg
authors: Syed, Maha N.; Shin, Daniel B.; Wan, Marilyn T.; Winthrop, Kevin L.; Gelfand, Joel M.
title: The Risk of Respiratory Tract Infections in Psoriasis Patients Treated With IL-23-pathway Inhibiting Biologics: A Meta-Estimate of Pivotal Trials Relevant to Decision-Making During the COVID-19 Pandemic
date: 2020-07-02
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.06.1014
sha: 83f00fd906cdd7b9ce5677bbdaa9f90e9caaacca
doc_id: 723567
cord_uid: tyexaefg

nan

However, data on the use of IL-23 inhibitors and its impact on the incidence and outcomes of 58 novel SARS-CoV-2 infection is limited. A Northern Italy study found that patients with psoriasis 59 on biologics had a higher risk for becoming infected with SARS-CoV-2 and hospitalization for 60 COVID-19 but saw no difference in mortality or use of a ventilator 4 . A case report observed 61 improvement in COVID-19 illness following guselkumab injection. 5 62 63

To evaluate the risk of RTIs associated with IL-23 biologic use, we analyzed data reported in 64 FDA approved phase 3 placebo-controlled clinical trials for guselkumab, risankizumab and 65 tildrakizumab from Food and Drug Administration prescribing information (PI) and 66 clinicaltrials.gov. To ensure uniformity, terms were reviewed to include only those consistent 67 with RTI. RTI events were divided by the total number of subjects at risk in each study and 68 compared to the placebo group by a meta-estimate. In PI, we found an increased risk of RTI in 69

the IL-23 groups as compared to placebo but this did not achieve statistical significance (OR In summary, we did not observe a statistically significant signal for RTI in psoriasis patients 78 treated with IL-23 biologics. While we did observe a statistically significant increased risk of 79 RTI using the same analysis approach with IL-17 biologics, we note that the confidence intervals 80 overlap with our current analysis, and therefore we cannot conclude with certainty that there is a 81 true difference in RTI risk between biologics that target IL-17 versus IL-23. There were greater 82 than 900 more patients treated with IL-17 biologics, and therefore, sample size may explain the 83 different statistical results. Due to the highly variable course of COVID-19, and the potential 84 differences between COVID-19 and other pathogens, large studies with appropriate 85 epidemiological methods are still needed to determine if IL-17/23 targeted biologics 86 meaningfully alter the risk of COVID-19 in patients with psoriasis. 87 88 89 Table 1 . Meta-estimate of respiratory tract infections from prescribing information 90 adverse events tables (includes "upper respiratory tract infections", "nasopharyngitis", 91

"respiratory tract infection (viral, bacterial and unspecified)", "influenza", "sinusitis (including 92 acute)", "pharyngitis (including viral)", "tonsillitis", "rhinitis") 93 Table 2 . Meta-estimate of respiratory tract infections from clinicaltrials.gov in phase 3 115 randomized control trials that were submitted for FDA approval* (includes: "upper 116 respiratory tract infections", "viral upper respiratory tract infections", "influenza", 117

"chylothorax", "sinusitis," , "bronchitis," "tonsillitis", "nasopharyngitis, "pneumonia") 118 The COVID-19 pandemic caused by the severe acute respiratory syndrome virus (SARS-CoV-2) 213 has led to uncertainty regarding the safety of immunosuppressive psoriasis therapy. We recently 214

reported a meta-estimate which demonstrated a 30-60% increase in the risk of respiratory tract 215 infections (RTI) in psoriasis patients receiving interleukin-17 (IL-17) biologics compared to 216 placebo 1 . Similar to IL-17, IL-23 is a key cytokine in the maintenance of T-helper 17 cells, 217

which mediates protection against pathogens. Although not believed to be a central cytokine in 218 the defense of viral infections, reduced levels of IL-23 may contribute to impairment of mucosal 219 barrier immunity resulting in an increased risk of respiratory infections 2 . Biologics which 220 specifically target IL-23 have high efficacy for psoriasis and a favorable risk-benefit profile 3 . 221

However, data on the use of IL-23 inhibitors and its impact on the incidence and outcomes of 222 novel SARS-CoV-2 infection is limited. A Northern Italy study found that patients with psoriasis 223 on biologics had a higher risk for becoming infected with SARS-CoV-2 and hospitalization for 224 COVID-19 but saw no difference in mortality or use of a ventilator 4 . A case report observed 225 improvement in COVID-19 illness following guselkumab injection. 5 226 227

To evaluate the risk of RTIs associated with IL-23 biologic use, we analyzed data reported in 228 FDA approved phase 3 placebo-controlled clinical trials for guselkumab, risankizumab and 229 tildrakizumab from Food and Drug Administration prescribing information (PI) and 230 clinicaltrials.gov. To ensure uniformity, terms were reviewed to include only those consistent 231 with RTI. RTI events were divided by the total number of subjects at risk in each study and 232

compared to the placebo group by a meta-estimate. In PI, we found an increased risk of RTI in 233

the IL-23 groups as compared to placebo but this did not achieve statistical significance (OR "respiratory tract infection (viral, bacterial and unspecified)", "influenza", "sinusitis (including 256 acute)", "pharyngitis (including viral)", "tonsillitis", "rhinitis") 257 Table 2 . Meta-estimate of respiratory tract infections from clinicaltrials.gov in phase 3 277 randomized control trials that were submitted for FDA approval* (includes: "upper 278 respiratory tract infections", "viral upper respiratory tract infections", "influenza","epiglottitis"," 279 "pneumonia staphylococcal", "chylothorax", "sinusitis," , "bronchitis," "tonsillitis", 280 "nasopharyngitis, "pneumonia") 281 

The risk of respiratory tract infections and